Promising Phase 3 Results for Alzheimer's Drug Donanemab
In a phase 3 trial, the monoclonal antibody donanemab slowed clinical and functional decline by 35% for patients with early Alzheimer's disease. However, the drug was not without safety issues.
Medscape Medical News
source https://www.medscape.com/viewarticle/994424?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/994424?src=rss
Comments
Post a Comment